High novel oncogene with kinase-domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma

Clinical Laboratory

Volumn 62, Issue 1-2, 2016, Pages 179-186

  Cao, Qingfei ^a   Chen, Meixue ^a   Li, Zizhi ^a   Huang, Weichao ^a   Jin, Yanyang ^a   Ye, Xiongjun ^b   Tong, Ming ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

NOK; Oncogene; Prognosis; Rcc

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ONCOGENE WITH KINASE DOMAIN; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE; STYK1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; FOLLOW UP; FUHRMAN GRADE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MTT ASSAY; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RENAL CANCER CELL LINE; WESTERN BLOTTING; AGED; CANCER GRADING; CARCINOMA, RENAL CELL; CELL MOTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TIME FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPHRECTOMY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962597859     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2015.150626     Document Type: Article

References (25)

1. Matsuura K, Nakada C, Mashio M., et al. Downregulation of SAVI plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer 2011; 11 (1):523.
2. Miyamoto H, Miller JS, Fajardo D.A., Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: The 2004 WHO/ ISUP classification system. Pathol Int 2010;60(1): 1-8.
3. Montironi R, Santinelli A, Pomante R., et al. Morphometric index of adult renal cell carcinoma. Virchows Arch 2000;437(1):82-9.
4. Cindolo L, Patard JJ, Chiodini P, et al Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 2005;104(7):1362-71.
5. Jiang Z, Chu PG, Woda B.A., et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res 2008; 14(17):5579-84.
6. Kim SP, Alt AL, Weight C.J., et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol 2011;185(6):2035-9.
7. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001;411(6835):355-65.
8. Liu L, Yu XZ, Li T.S., et al. A novel protein tyrosine kinase NOK that shares homology with platelet-derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res 2004;64(10):3491-9.
9. Cohen D, Lane B, Jin T., et al. The Prognostic Significance of Epidermal Growth Factor Receptor Expression in Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation. Clin Genitourin Cancer 2007;5(4): 264-70.
10. Tsimafeyeu I, Demidov L, Stepanova E., Wynn N, Ta H. Overex pression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol 2011;45(3): 190-5.
11. Kimbro KS, Duschene K, Willard M., Moore JA, Freeman S. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol Biol Rep 2008;35(1):23-7.
12. Amachika T, Kobayashi D, Moriai R., Tsuji N, Watanabe N. Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer 2007; 56(3):337-40.
13. Chung S, Tamura K, Furihata M., et al. Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. Cancer Sci 2009;100(11):2109-14.
14. Chen Y, Li YH, Chen X.P., et al. Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res 2005;65(23):10838-46.
15. Fisseler-Eckhoff A. Neue TNM-Klassifikation maligner Lungentumoren 2009 aus Sicht der Pathologie [New TNM classification of malignant lung tumors 2009 from a pathology perspective]. Pathologe 2009;30(2): 193-9 [Article in German].
16. Sinn BV, von Minckwitz G, Denkert C, et al Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol 2013 Sep;24(9):2316-24.
17. Szulc J, Wiznerowicz M, Sauvain M.O., Trono D., Aebischer P. A versatile tool for conditional gene expression and knockdown. Nat Methods 2006;3(2): 109-16.
18. Su F, Ren F, Rong Y., et al. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res 2012;14(2):R38.
19. Liang CC, Park AY, Guan JL In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007;2(2):329-33.
20. Edge SB, Compton CC The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17(6): 1471-4.
21. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J SurgPathol 1982;6(7):655-64.
22. Figlin R.A., Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORCl inhibitors. Int J Cancer 2013; 133(4):788-96.
23. Gollob JA, Wilhelm S, Carter C., Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33(4):392-406.
24. Merseburger AS, Hennenlotter J, Kuehs U., et al. Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int 2008;80(4):372-7.
25. Campbell L, Nuttall R, Griffiths D., Gumbleton M. Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer 2009; 115(15):3457-67.